Month: November 2020

Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial

Correction: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, November 13, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) publishes corrected information about the following transactions...

Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals,...

NextGen Healthcare Named Only Ambulatory-Specific EMR Vendor to Provide Strong Usability Experience in Latest KLAS Interoperability Report

Integrated Platform Provides Enhanced Ability for Providers to Exchange Clinical Data and Improve Patient Care IRVINE, Calif.--(BUSINESS WIRE)--$NXGN #AmbulatoryHealthcare--NextGen Healthcare,...

Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg

error: Content is protected !!